Acridones circumvent P-glycoprotein-associated multidrug resistance (MDR) in cancer cells
Vadiraj S Gopinath1, Padma Thimmaiah, Kuntebommanahalli N Thimmaiah
1Advinus Therapeutic Pvt. Ltd, 21 & 22, Phase-II, Peenya Industrial Area, Bangalore 560 058, India. vadiraj.gopinath@advinus.com
Abstract:
Multidrug resistance (MDR) mediated by overexpression of MDR1 P-glycoprotein (P-gp) is one of the best characterized transporter-mediated barriers to successful chemotherapy in cancer patients. Chemosensitizers are the agents that increase the sensitivity of multidrug-resistant cells to the toxic influence of previously less effective drugs. In an attempt to find such vital chemosensitizers, a series of N(10)-substituted-2-chloroacridone analogous (1-17) have been synthesized. Compound 1 was prepared by the Ullmann condensation of o-chlorobenzoic acid and p-chloroaniline followed by cyclization. The N-(omega-chloroalkyl) analogues were found to undergo iodide catalyzed nucleophilic substitution reaction with secondary amines and the resultant products were characterized by spectral methods. The lipophilicity expressed in log(10)P and pK(a) of compounds has been determined. All compounds were examined for their ability to increase the uptake of vinblastine (VLB) in MDR KBCh(R)-8-5 cells and the results showed that the compounds 6, 8, 11-14, 16, and 17 at their respective IC(50) concentrations caused a 1.0- to 1.7-fold greater accumulation of VLB than did a similar concentration of the standard modulator, verapamil (VRP). Results of the efflux experiment showed that VRP and each of the modulators significantly inhibited the efflux of VLB, suggesting that they may be competitors for P-gp. All modulators effectively competing with [(3)H]azidopine for binding to P-gp pointed out this transport membrane protein as their likely site of action. Compounds at IC(10) were evaluated for their efficacy to modulate the cytotoxicity of VLB and the results showed that modulators 11, 13, 14, 16, and 17 were able to completely reverse the 25-fold resistance of KBCh(R)-8-5 cells to VLB. Examination of the relationship between lipophilicity and antagonism of MDR showed a reasonable correlation suggesting that hydrophobicity is one of the determinants of potency for anti-MDR activity of 2-chloroacridones. The results allowed us to draw preliminary conclusions about structural features of 2-chloroacridones important for MDR modulation.
Insights
Researchers synthesized novel 2-chloroacridone analogs to combat multidrug resistance (MDR) in cancer. Several compounds effectively increased chemotherapy drug uptake and reversed resistance by inhibiting P-glycoprotein (P-gp), showing promise as chemosensitizers.
Area of Science:
- Medicinal Chemistry
- Cancer Biology
- Pharmacology
Background:
- Multidrug resistance (MDR) mediated by P-glycoprotein (P-gp) overexpression is a major challenge in cancer chemotherapy.
- Chemosensitizers can restore the efficacy of chemotherapeutic agents in MDR cancer cells.
Purpose of the Study:
- To synthesize and evaluate novel N(10)-substituted-2-chloroacridone analogs as potential chemosensitizers.
- To investigate the mechanism of action of these compounds in overcoming MDR.
Main Methods:
- Synthesis of N(10)-substituted-2-chloroacridone analogs via Ullmann condensation and nucleophilic substitution.
- Determination of lipophilicity (log(10)P) and pK(a).
- Assays for vinblastine (VLB) uptake, VLB efflux inhibition, and [(3)H]azidopine binding to P-gp.
- Evaluation of cytotoxicity modulation and reversal of VLB resistance.
Main Results:
- Compounds 6, 8, 11-14, 16, and 17 significantly increased VLB accumulation in MDR cells compared to verapamil.
- These modulators inhibited VLB efflux and competed with [(3)H]azidopine for P-gp binding, indicating P-gp as the target.
- Modulators 11, 13, 14, 16, and 17 completely reversed a 25-fold resistance to VLB.
- Lipophilicity correlated with MDR modulating activity.
Conclusions:
- Novel 2-chloroacridone analogs demonstrate significant potential as chemosensitizers to overcome P-gp-mediated MDR.
- Hydrophobicity is a key determinant for the anti-MDR activity of these compounds.
- Further structural optimization could lead to more potent MDR modulators for cancer therapy.
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

